# US 2022/0356070 A1 · Medical calcium carbonate composition, related medical compositions, and production methods therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0356070 A1
- Document ID: US20220356070A1
- Status: Published application
- Kind: A1
- Application number: 17/638,001
- Filed: 2020-08-27
- Published: 2022-11-10
- Earliest claimed: 2019-08-27
- Assignees: Kunio ISHIKAWA; GC Corporation
- Applicants: Kunio ISHIKAWA; GC Corporation
- Inventors: Kunio ISHIKAWA; Kanji TSURU; Riki TOITA; Yasuharu NAKASHIMA
- Web page: https://patentgrep.com/patent/US20220356070A1

## CPC

- C01B 25/32: Phosphates of magnesium, calcium, strontium, or barium
- C01F 11/18: Carbonates
- A61K 33/10: Carbonates; Bicarbonates
- A61L 27/12: Phosphorus-containing materials, e.g. apatite
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- C01F 11/181: {Preparation of calcium carbonate by carbonation of aqueous solutions and characterised by control of the carbonation conditions}
- C01F 11/184: {Preparation of calcium carbonate by carbonation of solutions based on non-aqueous solvents}
- C12M 25/14: {Scaffolds; Matrices (in general C12N5/0068)}
- A61L 2400/08: Methods for forming porous structures using a negative form which is filled and then removed by pyrolysis or dissolution
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- C01P 2002/72: by d-values or two theta-values, e.g. as X-ray diagram
- C01P 2004/03: obtained by SEM
- C01P 2004/32: Spheres
- C01P 2004/51: Particles with a specific particle size distribution
- C01P 2004/52: highly monodisperse size distribution
- C01P 2004/53: bimodal size distribution
- C01P 2004/61: Micrometer sized, i.e. from 1-100 micrometer
- C01P 2006/10: Solid density
- C01P 2006/12: Surface area
- C01P 2006/14: Pore volume
- C01P 2006/16: Pore diameter
- C01P 2006/80: Compositional purity
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- C01F: COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts of peroxyacids C01B15/00; sulfides or polysulfides of magnesium, calcium, strontium, or barium C01B17/42; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds other than ammonia or cyanogen containing nitrogen and non-metals and optionally metals C01B21/082; amides or imides of silicon C01B21/087}; metal {imides or} amides C01B21/092, {C01B21/0923}; nitrites C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; compounds having molecular sieve properties but not having base-exchange properties C01B37/00; compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites, C01B39/00; cyanides C01C3/08; salts of cyanic acid C01C3/14; salts of cyanamide C01C3/16; thiocyanates C01C3/20; {double sulfates of magnesium with sodium or potassium C01D5/12; with other alkali metals C01D15/00, C01D17/00})
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C01P: INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS

## Abstract

Provided is a medical calcium carbonate composition that highly satisfies 1) tissue affinity, 2) in vivo resorbability, 3) reactivity, and 4) mechanical strength required for medical materials to be implanted in vivo, a medical calcium phosphate composition, a medical carbonate apatite composition, a medical calcium hydroxide porous structure, a medical calcium sulfate setting granules, and a bone defect regeneration kit related to the medical calcium carbonate composition, and methods for producing these. The medical composition calcium carbonate that highly satisfies the above described elements, and related medical compositions can be produced by controlling the polymorph or structure of calcium carbonate.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

A bone defect reconstruction kit comprising a solid portion that contains vaterite and α-tricalcium phosphate and a liquid portion that contains phosphoric acid salt, and set to form carbonate apatite when the solid portion and liquid portion are mixed.

### Claim 38 (depends on 37)

The bone defect reconstruction kit according to claim 37 wherein amount of vaterite in the solid portion is 10 mass % or larger and 60 mass % or smaller.

### Claim 39 (depends on 37)

The bone defect reconstruction kit according to claim 37, wherein the liquid portion contains at least one selected from, acid containing plural carboxy groups, hydrogen sulfite salt, cellulose derivative, dextran sulfate salt, chondroitin sulfate salt, alginic acid salt, glucomannan.

### Claim 40 (depends on 37)

The bone defect reconstruction kit according to claim 37, wherein the volume of vaterite in the solid portion is 10−12 m3 or larger.

### Claim 41 (depends on 37)

The bone defect reconstruction kit according to claim 37, wherein the vaterite's average diameter is 6 μm or smaller.

### Claim 42

A medical calcium carbonate composition that satisfies all conditions of the following (A)-(C), and at least one condition selected from the group consisting of (D)-(K):
(A) a volume is 10−12 m3 or larger;
(B) remaining materials after acid dissolution are 1.0 mass % or less;
(C) it is substantially a pure calcium carbonate as a medical composition, and mainly comprises vaterite or calcite;
(D) it contains 20 mass % or larger of vaterite;
(E) it is a honeycomb structure comprising a plurality of through-holes extending in one direction, wherein a volume of pores which pore diameter is 10 μm or smaller with respect to a mass of the honeycomb structure analyzed by mercury intrusion porosimetry is larger than 0.02 cm3/g;
(F) it is a granule bonded-porous structure comprising a plurality of granules which maximum diameter is 50 μm or longer and 500 μm or shorter, formed by being bonded to each other, and comprising a plurality of through-holes extending in plural directions, wherein a volume of pores with a pore diameter of 10 μm or smaller analyzed by mercury intrusion porosimetry is 0.05 cm3/g or more;
(G) it is a pore integrated-type porous structure wherein a plurality of pores which maximum diameter is 50 μm or longer and 400 μm or shorter is integrated to the whole medical composition, not containing pores which maximum diameter is 800 μm or longer, wherein a volume of pores which maximum diameter is 10 μm or smaller in the pore integrated-type porous structure analyzed by mercury intrusion porosimetry is 0.05 cm3/g or more;
(H) a ratio of pore volume which pore diameter is 1 μm or larger and 6 μm or shorter with respect to a pore volume which pore diameter is 6 μm or shorter analyzed by mercury intrusion porosimetry is 10% or more;
(I) a maximum compressive strength obtained at any one direction is higher than a standard compressive strength [S] that is calculated by the following equation (with the proviso that a honeycomb structure comprising a plurality of through-holes extending in one direction, wherein a volume of pores with a pore diameter of 10 μm or smaller with respect to a mass of the honeycomb structure analyzed by mercury intrusion porosimetry is 0.02 cm3/g or smaller is excluded)
S=S0×C×exp(−b×P)
wherein S0 and b are constant number, S0 is 500, b is 0.068, and C is a constant number based on polymorph of calcium carbonate; C is 0.01 when the calcium carbonate contains 20 mass % or larger of vaterite, and is 1 when the calcium carbonate does not contain 20 mass % or larger of vaterite; and P is a percentage of pores in the composition);
(J) it is a honeycomb structure granule which minor diameter is 1 mm or larger, and shorter than 5 mm, wherein, when a circle with a radius of 0.2 mm from any point on a peripheral line of a perspective image is depicted, and at a triangle formed by three points: the vertex point on the peripheral line and two points made by an intersection of the circle and a line of perspective image, no vertex point that the interior angle is 90° or smaller at the triangle exists;
(K) plural composition particles are connected with a fiber.

### Claim 43 (depends on 42)

The medical calcium carbonate composition according to claim 42,
wherein calcium carbonate powders that satisfy at least one of the following (AJ1) to (AJ4) conditions, are bonded to form the calcium carbonate composition:
(AJ1) a mean particle diameter is 2 μm or larger, and 8 μm or smaller;
(AJ2) a sphericity is 0.9 or larger;
(AJ3) Mg content is 5×10−4 mass % or larger, and 3×10−3 mass % or smaller;
(AJ4) Sr content is 3×10−3 mass % or larger, and 1.5×10−2 mass % or smaller.

### Claim 44 (depends on 42)

A method for producing the medical calcium carbonate composition according to claim 42 that satisfies the above described (D) condition, wherein:
in a process of exposing raw material calcium composition which volume is 10−12 m3 or larger to carbon dioxide or carbonate ion, at least one of the following conditions selected from (D1) to (D8) group is satisfied, and optionally comprises the following (D9) to (D12) process:
(D1) a process of inhibiting calcite formation or calcite crystal growth, and relatively promoting vaterite formation;
(D2) a process of exposing of raw material calcium composition to carbon dioxide or carbonate ion, and at least one selected from the group consisting of organic solvent, water soluble organic material, ammonia, and ammonium salt;
(D3) a process of exposing raw material calcium composition that contains at least one selected from the group consisting of organic solvent, water soluble organic material, ammonia, and ammonium salt, to carbon dioxide or carbonate ion, and at least one selected from the group consisting of organic solvent, water soluble organic material, ammonia, and ammonium salt;
(D4) a process of exposing raw material calcium composition to carbon dioxide or carbonate ion, and at least one selected from the group consisting of methanol, ethanol, glycerin, ethylene glycol, and ammonium carbonate;
(D5) a process of exposing raw material calcium composition that contains at least one selected from the group consisting of methanol, ethanol, glycerin, ethylene glycol, and ammonium carbonate, to carbon dioxide or carbonate ion, and at least one selected from the group consisting of methanol, ethanol, glycerin, ethylene glycol, and ammonium carbonate;
(D6) a process of inhibiting transfer from vaterite to calcite;
(D7) a process of removing water from the raw material calcium composition;
(D8) a process of circulating carbon dioxide or carbonate ion containing organic solvent around the raw material calcium composition;
(D9) a process of partial carbonation by exposing raw material calcium composition to carbon dioxide or carbonate ion under gas phase, followed by exposing the raw material calcium composition to carbon dioxide or carbonate ion under liquid phase;
(D10) a process of exposing raw material calcium composition in a mold to carbon dioxide or carbonate ion;
(D11) a process of exposing raw material calcium composition that contains porogen to carbon dioxide or carbonate ion;
(D12) a process of exposing raw material calcium compositions that are connected with a fiber to carbon dioxide or carbonate ion.

### Claim 45 (depends on 42)

A method for producing the medical calcium carbonate composition according to claim 42 that satisfies the above described (E) condition, comprising:
the following process (E1) and one process selected from the group consisting of (E5) to (E9) as essential process, and optionally one process selected from the following (E2) to (E4), and (E10):
(E1) Extrusion process
a process of producing a raw honeycomb structure comprising a plurality of through-holes extending in one direction, having a volume of 3×10−11 m3 or larger by extruding a raw material calcium composition comprising polymer material through a honeycomb structure forming die;
(E2) Forming process after extrusion process
A process of forming honeycomb structure consisting of a raw material calcium composition comprising polymer material to a desired form by softening by a thermal treatment, followed by pressure loading;
(E3) Removal process of peripheral wall
A process of removing peripheral wall after the extrusion process or the forming process after the extrusion process, and before a debindering and carbonation process;
(E4) Forming process after removal process of peripheral wall
A process of forming a honeycomb structure consisting of a raw material calcium composition comprising polymer material to a desired form through softening by thermal treatment, after removal process of peripheral wall;
(E5) Debindering and calcium carbonate sintering process
a process of heat debindering of polymer material-containing calcium carbonate so that remaining materials after acid dissolution is 1 mass % or smaller, and sintering the calcium carbonate;
(E6) Debindering and carbonation process
a process of heat debindering of a polymer material containing-calcium hydroxide porous structure so that remaining materials after acid dissolution is 1 mass % or smaller under an oxygen concentration of less than 30%, and carbonation at the same time;
(E7) Debindering and carbonation process via calcium oxide
a process of heat debindering a polymer material containing-calcium hydroxide porous structure or polymer material containing-calcium carbonate porous structure so that remaining materials after acid dissolution is 1 mass % or smaller, and to be calcium oxide porous structure, followed by exposing the calcium oxide porous structure to carbon dioxide to be a calcium carbonate porous structure;
(E8) Debindering and carbonation process via calcium carbonate and calcium oxide
a process of heat treatment of a polymer material-containing calcium hydroxide under carbon dioxide atmosphere to be a polymer material containing-calcium carbonate porous structure, followed by heat debindering so that remaining materials after acid dissolution is 1 mass % or smaller, and to be a calcium oxide porous structure, followed by exposing the calcium oxide porous structure to carbon dioxide to be a calcium carbonate porous structure;
(E9) Debindering and carbonation process of calcium sulfate
a process of heat debindering of a polymer material containing-calcium sulfate so that remaining materials after acid dissolution is 1 mass % or smaller, followed by adding carbon dioxide or carbonate ion to the produced calcium sulfate porous structure to be a calcium carbonate;
(E10) a process of structure finishing process after debindering and carbonation processes.

### Claim 46 (depends on 42)

A method for producing the medical calcium carbonate composition according to claim 42 that satisfies the above described (F) condition, comprising:
the following (F1) and (F2) processes, and at least one of the (F3) or (F4) process:
(F1) Placement-closing process
placing calcium oxide granules in a reaction vessel, and closing the opening of the vessel so that the granules are not escaped from the reaction vessel;
(F2) Porous structure producing process
a process of producing a porous structure by adding water or acetic acid to the calcium oxide granules inside the reaction vessel to make calcium hydroxide or calcium acetate;
(F3) Carbonation process
a carbonation process to produce a calcium carbonate porous structure by adding carbon dioxide to calcium hydroxide porous structure at the same time or after the porous structure producing process, or a carbonation process to produce a calcium carbonate porous structure by heat treatment of calcium acetate after porous structure producing process;
(F4) Calcium oxide carbonation process
a carbonation process producing a calcium carbonate porous structure by heat treatment of at least one selected from a group consisting of calcium hydroxide porous structure, calcium carbonate porous structure, and calcium acetate porous structure, followed by exposing the calcium oxide porous structure to carbon dioxide.

### Claim 47 (depends on 42)

A method for producing the medical calcium carbonate composition according to claim 42 that satisfies the above described (F) condition, comprising the following (F10), (F11) and one selected from the group of (F12) to (F16) as essential processes, and optionally comprising the (F17) process:
(F10) Placement process
a process of placing raw material calcium composition granules containing polymer having a volume of 10−12 m3 or larger in a reaction vessel;
(F11) Porous structure forming process
A process of producing granules bonded-porous structure formed from a plurality of granules which maximum diameter is 50 μm or longer and 500 μm or shorter bonded to each another, and comprising a plurality of through-holes extending in plural directions, and having a volume of 3×1011 m3 by bonding the granules in the reaction vessel by heat fusing, or by fusing of the surface of granules to bond the surface of the granules one to another, or by fusing the surface of granules one to another with a plasticizer;
(F12) Debindering and calcium carbonate sintering process
a process of heat debindering of polymer material containing-calcium carbonate so that remaining materials after acid dissolution are 1 mass % or smaller, and sintering the calcium carbonate;
(F13) Debindering and carbonation process
a process of heat debindering of polymer material containing calcium hydroxide porous structure so that remaining materials after acid dissolution are 1 mass % or smaller under oxygen concentration of less than 30%, and carbonation at the same time;
(F14) Debindering and carbonation process via calcium carbonate and calcium oxide
a process of heat treatment of polymer material containing-calcium hydroxide porous structure or polymer material containing-calcium carbonate porous structure so that remaining materials after acid dissolution are 1 mass % or smaller, and to be calcium oxide porous structure, followed by exposing the calcium oxide porous structure to carbon dioxide to be calcium carbonate porous structure;
(F15) Debindering and carbonation process via calcium carbonate and calcium oxide
Debindering and carbonation process via calcium carbonate and calcium oxide, comprising heat treatment of polymer material-containing calcium hydroxide porous structure in the presence of carbon dioxide to produce polymer material-containing calcium carbonate porous structure, followed by heat debindering so that remaining materials after acid dissolution are 1 mass % or smaller, and to be calcium oxide porous structure, followed by exposing the calcium oxide porous structure to carbon dioxide to be calcium carbonate porous structure;
(F16) Calcium sulfate debindering and carbonation process
a debindering and carbonation process of producing calcium carbonate by heat debindering of polymer material-containing calcium sulfate so that remaining materials after acid dissolution are 1 mass % or smaller, followed by adding carbon dioxide or carbonate ion to the produced calcium sulfate porous structure;
(F17) A process of structure finishing process after debindering and carbonation processes.

### Claim 48 (depends on 44)

A method for producing the medical calcium carbonate composition according to claim 44 comprising: at least one process selected from a group of below described (L) to (Q) as essential process:
(L) A process of debindering done at an oxygen partial pressure of 30 KPa or higher;
(M) A process of debindering or carbonation done at carbon dioxide partial pressure of 30 KPa or higher;
(N) A process of debindering or carbonation done at 150 KPa or higher under atmosphere that contains oxygen or carbon dioxide;
(O) A process of increasing carbon dioxide concentration in the reaction vessel by replacing air in the reaction vessel partially or completely with carbon dioxide, followed by introduction of carbon dioxide in the reaction vessel;
(P) A process of supplying carbon dioxide so that the pressure of the closed reaction vessel is a constant value;
(Q) A carbonation process of mixing or circulating carbon dioxide in the reaction vessel.

### Claim 49 (depends on 44)

A method for producing the medical calcium carbonate composition according to claim 44, wherein: at least one condition selected from the following (R1) to (R4) is satisfied:
(R1) Using calcium carbonate powder with an average particle diameter of 2 μm and larger, and 8 μm and smaller;
(R2) Using calcium carbonate powder with a sphericity of 0.9 or higher;
(R3) Using calcium carbonate powder containing 5×10−4 mass % or larger, and 3×10−3 mass % or smaller of Mg;
(R4) Using calcium carbonate powder containing 3×10−3 mass % or larger, and 1.5×10−2 mass % or smaller of Sr.

### Claim 50

A medical calcium phosphate composition that satisfies all the following (V1) to (V3) conditions, and at least one condition selected from the group consisting of (V4) to (V10), and optionally satisfying (V11) or (V12):
(V1) a volume is 1×10−12 m3 or larger;
(V2) remaining materials after acid dissolution are 1.0 mass % or less;
(V3) it is substantially a pure calcium phosphate as medical composition and is one selected from the group consisting of carbonate apatite, apatite containing HPO4 group, tricalcium phosphate, whitlockite, calcium hydrogen phosphate;
(V4) it is a honeycomb structure comprising a plurality of through-holes extending in one direction (with the proviso that a honeycomb structure that does not satisfy any of the following condition is excluded: a composition is tricalcium phosphate, wherein a volume of pores which pore diameter is 10 μm or smaller with respect to a mass of the honeycomb structure analyzed by mercury intrusion porosimetry is 0.01 cm3/g or more; and a diameter of the circle that passes through both ends of any one of the through-holes and a center of the through-hole, is 1 cm or longer, and 50 cm or shorter; The surface roughness of the surface of partition wall of honeycomb structure along the through-holes direction in arithmetic average roughness (Ra) is 0.7 μm or larger);
(V5) it is a granule bonded-porous structure comprising a plurality of granules which maximum diameter is 50 μm or longer and 500 μm or shorter, formed by being bonded to each other, and comprising a plurality of through-holes extending in plural directions, wherein a volume of pores with a pore diameter of 10 μm or smaller analyzed by mercury intrusion porosimetry is 0.05 cm3/g or more;
(V6) it is a pore integrated-type porous structure wherein a plurality of pores which maximum diameter is 50 μm or longer and 400 μm or shorter is integrated to the whole medical composition, not containing pores which maximum diameter is 800 μm or longer, wherein a volume of pores which maximum diameter is 10 μm or smaller in the pore integrated-type porous structure analyzed by mercury intrusion porosimetry is 0.05 cm3/g or more (with the proviso that one which composition is tricalcium phosphate is excluded);
(V7) a volume of pores having a pore diameter of 6 μm or shorter with respect to a volume of pores having a pore diameter of 1 μm or larger and 6 μm or shorter analyzed by mercury intrusion porosimetry is 5% or more;
(V8) a maximum compressive strength obtained at any one direction is higher than a standard compressive strength [S] that is calculated by the following equation (with the proviso that a honeycomb structure comprising a plurality of through-holes extending in one direction, wherein a volume of pores with a pore diameter of 10 μm or smaller with respect to a mass of the honeycomb structure analyzed by mercury intrusion porosimetry is 0.02 cm3/g or smaller is excluded)
S=S0×C×exp(−b×P)
(wherein S0 and b are the constant, and S0 is 500, and b is 0.068, and C is the constant based on the composition; C is 1 for carbonate apatite, apatite containing HPO4, tricalcium phosphate, and C is 0.5 for whitlockite, and C is 0.1 for calcium hydrogen phosphate; and P is the percentage of pores in the composition);
(V9) it is a honeycomb structure granule which minor diameter is 1 mm or larger, and shorter than 5 mm, wherein, when a circle with a radius of 0.2 mm from any point on a peripheral line of a perspective image is depicted, and at a triangle formed by three points: the vertex point on the peripheral line and two points made by an intersection of the circle and a line of perspective image, no vertex point that the interior angle is 90° or smaller at the triangle exists;
(V10) The plural composition granules are connected with a fiber;
(V11) Composition is apatite with carbonate content is 10 mass % or larger;
(V12) Composition is apatite with carbonate content is smaller than 10 mass %.

### Claim 51 (depends on 50)

A method for producing the medical phosphate calcium composition according to claim 50, comprising adding phosphoric acid component to a medical calcium carbonate composition that satisfies all the conditions of (A) to (C), and at least one condition selected from the group of (D) to (K),
wherein the medical calcium carbonate composition is immersed in at least one of the aqueous solution selected from the group of (X1) to (X5), to add phosphoric component to the medical calcium carbonate composition:
(A) a volume is 10−12 m3 or larger;
(B) remaining materials after acid dissolution are 1.0 mass % or less;
(C) it is substantially a pure calcium carbonate as a medical composition, and mainly comprises vaterite or calcite;
(D) it contains 20 mass % or larger of vaterite;
(E) it is a honeycomb structure comprising a plurality of through-holes extending in one direction, wherein a volume of pores which pore diameter is 10 μm or smaller with respect to a mass of the honeycomb structure analyzed by mercury intrusion porosimetry is larger than 0.02 cm3/g;
(F) it is a granule bonded-porous structure comprising a plurality of granules which maximum diameter is 50 μm or longer and 500 μm or shorter, formed by being bonded to each other, and comprising a plurality of through-holes extending in plural directions, wherein a volume of pores with a pore diameter of 10 μm or smaller analyzed by mercury intrusion porosimetry is 0.05 cm3/g or more;
(G) it is a pore integrated-type porous structure wherein a plurality of pores which maximum diameter is 50 μm or longer and 400 μm or shorter is integrated to the whole medical composition, not containing pores which maximum diameter is 800 μm or longer, wherein a volume of pores which maximum diameter is 10 μm or smaller in the pore integrated-type porous structure analyzed by mercury intrusion porosimetry is 0.05 cm3/g or more;
(H) a ratio of pore volume which pore diameter is 1 μm or larger and 6 μm or shorter with respect to a pore volume which pore diameter is 6 μm or shorter analyzed by mercury intrusion porosimetry is 10% or more;
(I) a maximum compressive strength obtained at any one direction is higher than a standard compressive strength [S] that is calculated by the following equation (with the proviso that a honeycomb structure comprising a plurality of through-holes extending in one direction, wherein a volume of pores with a pore diameter of 10 μm or smaller with respect to a mass of the honeycomb structure analyzed by mercury intrusion porosimetry is 0.02 cm3/g or smaller is excluded)
S=S0×C×exp(−b×P)
(wherein S0 and b are constant number, S0 is 500, b is 0.068, and C is a constant number based on polymorph of calcium carbonate; C is 0.01 when the calcium carbonate contains 20 mass % or larger of vaterite, and is 1 when the calcium carbonate does not contain 20 mass % or larger of vaterite; and P is a percentage of pores in the composition);
(J) it is a honeycomb structure granule which minor diameter is 1 mm or larger, and shorter than 5 mm, wherein, when a circle with a radius of 0.2 mm from any point on a peripheral line of a perspective image is depicted, and at a triangle formed by three points: the vertex point on the peripheral line and two points made by an intersection of the circle and a line of perspective image, no vertex point that the interior angle is 90° or smaller at the triangle exists;
(K) plural composition particles are connected with a fiber;
(X1) Aqueous solution containing phosphoric acid component with pH 8.5 or higher;
(X2) Aqueous solution containing phosphoric acid component with pH lower than 8.5;
(X3) Aqueous solution containing both phosphoric acid component and carbonate component at a concentration of 0.5 mol/L or lower of pH 8.5 or higher;
(X4) Aqueous solution containing both phosphoric acid component and carbonate component at a concentration of 0.5 mol/L or lower of pH lower than pH 8.5;
(X5) Aqueous solution containing both phosphoric acid component and magnesium component.
